Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations.

× No keyword cloud information.

13 in total

1. The challenges of determining noninferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants.

Authors: Grace Wangge; Kit C B Roes; Anthonius de Boer; Arno W Hoes; Mirjam J Knol
Journal: CMAJ Date: 2012-08-20 Impact factor: 8.262

Review 2. Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation.

Authors: Katherine P Cabral; Jack Ansell
Journal: Nat Rev Cardiol Date: 2012-02-28 Impact factor: 32.419

3. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation.

Authors: Hooman Kamel; J Donald Easton; S Claiborne Johnston; Anthony S Kim
Journal: Neurology Date: 2012-09-19 Impact factor: 9.910

4. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors: James F Meschia; Cheryl Bushnell; Bernadette Boden-Albala; Lynne T Braun; Dawn M Bravata; Seemant Chaturvedi; Mark A Creager; Robert H Eckel; Mitchell S V Elkind; Myriam Fornage; Larry B Goldstein; Steven M Greenberg; Susanna E Horvath; Costantino Iadecola; Edward C Jauch; Wesley S Moore; John A Wilson
Journal: Stroke Date: 2014-10-28 Impact factor: 7.914

Review 5. Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Authors: Natalie J Carter; Greg L Plosker
Journal: Drugs Date: 2013-05 Impact factor: 9.546

6. On robustness of noninferiority clinical trial designs against bias, variability, and nonconstancy.

Authors: Qing Liu; Yulan Li; Katherine Odem-Davis
Journal: J Biopharm Stat Date: 2015 Impact factor: 1.051

7. A systems approach to designing effective clinical trials using simulations.

Authors: Vincent A Fusaro; Prasad Patil; Chih-Lin Chi; Charles F Contant; Peter J Tonellato
Journal: Circulation Date: 2012-12-21 Impact factor: 29.690

8. A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.

Authors: Akinori Sairaku; Yukihiko Yoshida; Monami Ando; Haruo Hirayama; Yukiko Nakano; Yasuki Kihara
Journal: Clin Drug Investig Date: 2013-11 Impact factor: 2.859

9. Rivaroxaban in atrial fibrillation.

Authors: Mariano A Giorgi; Lucas San Miguel
Journal: Vasc Health Risk Manag Date: 2012-08-30

10. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database.

Authors: Sally Lee; Brigitta U Monz; Andreas Clemens; Martina Brueckmann; Gregory Y H Lip
Journal: BMJ Open Date: 2012-12-14 Impact factor: 2.692